How automation helps protect data quality across expanding studies
As biomarker programs progress from small-scale discovery to large validation studies, reproducibility becomes a core challenge. Larger sample sets, multi-site collaborations and regulatory scrutiny require assays that are consistent, high-throughput and transferable between laboratories. Yet scaling up without automation can introduce variability, compromising data integrity and delaying decisions.
Why biomarker workflows become harder to control at scale
Increasing sample volumes and assay frequency without sacrificing result accuracy and precision
Ensuring standardized protocols and harmonized data across different labs or trial sites
Maintaining validated, traceable processes and data
Automation is a pivotal response to these challenges. Automated workflows reduce human variation, enforce standard protocols and support real-time tracking at every step, improving reproducibility and throughput simultaneously. But consistent results at scale do not come from automating a single task. They depend on connecting automation across the biomarker workflow.
Where automation strengthens reproducibility
1. Sample preparation
The Biomek i-Series and Echo acoustic liquid handler automate assay preparation to reduce human error and variability. Available software features support audit trails, traceability and 21 CFR Part 11 compliance in regulated workflows.
2. Assay execution
CellXpress.ai standardizes cell culture and monitoring, while SpectraMax systems support consistent microplate-based detection, helping reduce operator-dependent variability across cell-based assay workflows.
3. Analyte separation
Biozen and Kinetex LC column consumables provide robust, highly efficient separations for LC/MS workflows, helping control variability before detection and quantitation, particularly as sample numbers increase.
4. Quantitation and quality control
The ZenoTOF 8600 and SCIEX 7500+ systems provide high-precision mass spec with standardized workflows and built-in QC, delivering sensitive, consistent quantitation across runs and sites, even for complex protein analytes.
We See a Way to increase confidence in biomarker discovery and validation with up to 10x greater sensitivity, and quantitative data that scales
SCIEX | ZenoTOF 8600 system
What a connected automation strategy looks like
Scaling biomarker assays with automation is not about a single technology but an end-to-end connected strategy. By aligning validated reagents, automated workflows and high-precision analytical platforms, biomarker teams can transform fragmented processes into scalable, reproducible systems. The strongest strategies also connect instruments and methods with consistent quality controls, metadata and audit trails so results can be traced and compared across laboratories and over time.
Three questions to ask before scaling
- Where does variability enter the workflow? Map manual handoffs, operator-dependent steps and inconsistent data capture before selecting automation priorities
- Can the process transfer between sites? Define shared protocols, controls and acceptance criteria that support comparable performance across laboratories
- Is traceability designed in from the start? Ensure methods, samples, instruments and results can be tracked as the program expands
From reproducibility challenges to translational confidence
When automation is integrated across the workflow, biomarker teams can increase throughput without treating consistency as a tradeoff. More reproducible processes strengthen confidence in data-driven decisions, improve cross-study comparability and help programs advance toward clinical translation with fewer avoidable delays.
Explore how connected automation can strengthen reproducibility, accelerate biomarker development and build confidence from discovery through validation.
